Scroll Top
Menu
Close
About us
Overview
Leadership Team
Board of Directors
Clinical Advisory Board
Partners
Careers
Science and Technology
Platform Technology
Science
Posters
Publications
Pipeline
Investors & Media
Overview
News & Events
Stock Information
Analyst Coverage
Investor Resources
SEC Filings
Governance Documents
Contact Us
Perspectives
Events and Team Interviews
Parkinson 101
Technical Articles
Menu
Close
About us
Overview
Leadership Team
Board of Directors
Clinical Advisory Board
Partners
Careers
Science and Technology
Platform Technology
Science
Posters
Publications
Pipeline
Investors & Media
Overview
News & Events
Stock Information
Analyst Coverage
Investor Resources
SEC Filings
Governance Documents
Contact Us
Perspectives
Events and Team Interviews
Parkinson 101
Technical Articles
Home
»
Early data suggest GT-02287 slows Parkinson’s disease - Perspectives from Gain Therapeutics
Related Posts
Menu
Close
About us
Overview
Leadership Team
Board of Directors
Clinical Advisory Board
Partners
Careers
Science and Technology
Platform Technology
Science
Posters
Publications
Pipeline
Investors & Media
Overview
News & Events
Stock Information
Analyst Coverage
Investor Resources
SEC Filings
Governance Documents
Contact Us
Perspectives
Events and Team Interviews
Parkinson 101
Technical Articles
Related Posts
Early data suggest GT-02287 slows Parkinson’s disease
Drug Discovery World
Oct 08, 2025
Early data suggest GT-02287 slows Parkinson’s disease
Related Posts
Post navigation
Previous Post
New Parkinson’s Drug GT-02287 Shows Promising Phase 1b Data
Next Post
Allosteric small molecule therapies in PD, with Gene Mack
Latest Articles
Clear Filters
June 10, 2026
Four emerging technologies reshaping neurology in 2026
https://www.labiotech.eu/in-depth/neurology-technology/
Read More
June 9, 2026
Bial drops pariceract after Phase IIb failure in GBA-associated Parkinson’s
https://european-biotechnology.com/latest-news/bial-drops-pariceract-after-phase-iib-failure-in-gba-associated-parkinsons/
Read More
May 27, 2026
Gain Therapeutics expands ‘compelling’ evidence base for Parkinson’s candidate
https://finance.yahoo.com/sectors/healthcare/articles/gain-therapeutics-expands-compelling-evidence-043446986.html
Read More
Close
About us
Overview
Leadership Team
Board of Directors
Clinical Advisory Board
Partners
Careers
Science and Technology
Platform Technology
Science
Posters
Publications
Pipeline
Investors & Media
Overview
News & Events
Stock Information
Analyst Coverage
Investor Resources
SEC Filings
Governance Documents
Contact Us
Perspectives
Events and Team Interviews
Parkinson 101
Technical Articles